A survey to assess the prevalence of Hepatitis B in the adult HIV positive population of the TC Newman ARV centre, Paarl

Simple item page
dc.contributor.advisorHagemeister, Dirken_ZA
dc.contributor.authorKing, Jeanmarien_ZA
dc.contributor.authorBotha, Jeanmarien_ZA
dc.contributor.otherStellenbosch University. Faculty of Health Sciences. Dept. of Interdisciplinary Health Sciences.en_ZA
dc.date.accessioned2015-07-23T05:17:09Z
dc.date.available2015-07-23T05:17:09Z
dc.date.issued2011-08
dc.descriptionThesis (MBchB)--Stellenbosch University, 2016en_ZA
dc.description.abstractENGLISH ABSTRACT: Background: Hepatitis B Virus (HBV) and Human Immunodeficiency Virus (HIV) co-infection in South Africa is estimated between 5-17%; however research determining this prevalence is lacking. With co-infection there is increased risk of liver cirrhosis, end stage liver disease, death as well as higher rates of chronic Hepatitis B infection. Chronic HBV develops in 20% of HIV positive individuals when compared to less than 5% in HIV negative individuals. This also further complicates Highly Active AntiRetroviral Treatment (HAART). Methods: A retrospective observational quantitative, cross-sectional, analytical study was done at the TC Newman Antiretroviral (ARV) centre in Paarl. All adult HIV positive patients that were started on antiretroviral therapy for the time period the new protocol was implemented were analyzed according to their Hepatitis B Antigen (HBsAg) result as well as for any association with gender, CD4 and age. The new protocol stated that all patients who were to start ARV’s had to be tested for Hepatitis B by testing their HBsAg. Results: A total of 498 participants were identified of which 40% were male and 60% were female. The HBsAg positivity rate was established at 7.6%. A higher prevalence was found among men as well as in the age group 50-59 years and those with a CD4 of 50/μL and less. Conclusions: With a prevalence of almost 8% there should definitely be a recommendation towards routine testing of HIV positive patients for Hepatitis B. If not before commencing ART then at least when switching from a regimen containing Lamivudine (3TC) or Tenofovir (TDF) to a regimen not containing these drugs in order to prevent acute flare ups of hepatitis.en_ZA
dc.format.extent18 pagesen_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/97222
dc.language.isoen_ZAen_ZA
dc.publisherStellenbosch : Stellenbosch Universityen_ZA
dc.rights.holderStellenbosch Universityen_ZA
dc.subjectHepatitis B virusen_ZA
dc.subjectHepatitis virusesen_ZA
dc.subjectHepatitis B -- Treatmenten_ZA
dc.subjectHepatitis B -- Treatment -- Complicationsen_ZA
dc.subjectHIV-positive persons -- Africa, Southernen_ZA
dc.subjectHAART (Chemotherapy)en_ZA
dc.subjectHigly active antiretroviral therapyen_ZA
dc.subjectUCTD
dc.titleA survey to assess the prevalence of Hepatitis B in the adult HIV positive population of the TC Newman ARV centre, Paarlen_ZA
dc.typeThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
king_survey_2015.pdf
Size:
800.29 KB
Format:
Adobe Portable Document Format
Description:
Download PDF
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Masters Degrees (Family Medicine and Primary Care)